These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36935855)

  • 1. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
    Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
    Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study.
    Nicosia L; Franceschini D; Perrone-Congedi F; Casamassima F; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Alicino G; Frassinelli L; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Corti L; Vavassori V; Maranzano E; Magrini SM; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Livi L; Jereczek-Fossa BA; Osti MF; Scorsetti M; Alongi F
    Radiother Oncol; 2022 Jan; 166():92-99. PubMed ID: 34748855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
    Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
    Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients.
    Nicosia L; Figlia V; Ricottone N; Cuccia F; Mazzola R; Giaj-Levra N; Ricchetti F; Rigo M; Jafari F; Maria Magrini S; Girlando A; Alongi F
    Clin Exp Metastasis; 2022 Aug; 39(4):581-588. PubMed ID: 35511313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
    Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
    Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
    Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
    Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
    Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.
    Mihai A; Mu Y; Armstrong J; Dunne M; Beriwal S; Rock L; Thirion P; Heron DE; Bird BH; Westrup J; Murphy CG; Huq MS; McDermott R
    J Radiosurg SBRT; 2017; 5(1):43-53. PubMed ID: 29296462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
    Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
    BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.
    Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P
    Front Oncol; 2022; 12():863609. PubMed ID: 35494057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases.
    Billiet C; Joye I; Mercier C; Depuydt L; De Kerf G; Vermeulen P; Van Laere S; Van de Kelft E; Meijnders P; Verellen D; Dirix P
    Clin Transl Radiat Oncol; 2020 Sep; 24():65-70. PubMed ID: 32642561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of lung oligometastatic patients treated with stereotactic body irradiation.
    Virbel G; Cox DG; Olland A; Falcoz PE; Le Fevre C; Schott R; Antoni D; Noel G
    Front Oncol; 2022; 12():945189. PubMed ID: 36003767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy.
    Bauman GS; Corkum MT; Fakir H; Nguyen TK; Palma DA
    BMC Cancer; 2021 Apr; 21(1):405. PubMed ID: 33853550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
    Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
    Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
    Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.
    Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.